Integra Lifesciences Holdings (Integra Lifesciences Holdings) Interest Coverage

: 2.62 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Integra Lifesciences Holdings's Operating Income for the three months ended in Dec. 2023 was $36 Mil. Integra Lifesciences Holdings's Interest Expense for the three months ended in Dec. 2023 was $-14 Mil. Integra Lifesciences Holdings's interest coverage for the quarter that ended in Dec. 2023 was 2.62. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Integra Lifesciences Holdings's Interest Coverage or its related term are showing as below:

IART' s Interest Coverage Range Over the Past 10 Years
Min: 1.28 Med: 3.02 Max: 4.82
Current: 2.17

IART's Interest Coverage is ranked worse than
88.26% of 426 companies
in the Medical Devices & Instruments industry
Industry Median: 19.59 vs IART: 2.17

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Integra Lifesciences Holdings Interest Coverage Historical Data

The historical data trend for Integra Lifesciences Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Integra Lifesciences Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

2.94

2.11

3.91

4.82

2.17

Integra Lifesciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage																5.26	3.01	1.00	2.04	2.62

Competitive Comparison

For the Medical Devices subindustry, Integra Lifesciences Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integra Lifesciences Holdings Interest Coverage Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Interest Coverage falls into.

Integra Lifesciences Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Integra Lifesciences Holdings's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Integra Lifesciences Holdings's Interest Expense was $-51 Mil. Its Operating Income was $112 Mil. And its Long-Term Debt & Capital Lease Obligation was $1,652 Mil.

Interest Coverage	=	-1	*	Operating Income (A: Dec. 2023 )	/	Interest Expense (A: Dec. 2023 )
	=	-1	*	111.526	/	-51.377
	=	2.17

Integra Lifesciences Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Integra Lifesciences Holdings's Interest Expense was $-14 Mil. Its Operating Income was $36 Mil. And its Long-Term Debt & Capital Lease Obligation was $1,652 Mil.

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	36.047	/	-13.751
	=	2.62

The higher the ratio, the stronger the company's Financial Strength is.

Integra Lifesciences Holdings (NAS:IART) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Integra Lifesciences Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

IL3:Germany

Address

1100 Campus Road, Princeton, NJ, USA, 08540

Website

https://www.integralife.com

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Executives

Chantal Veillon-berteloot	officer: EVP & CHRO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook	officer: SVP, Fin & PAO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight	officer: EVP & CFO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz	officer: Corp VP, Gen Counsel & Sec	C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De	director, officer: President & CEO	C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen	officer: Executive VP & President, CSS	1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh	officer: Exec VP & PRES, International	1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli	officer: Chief Human Resources Officer	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy	director	14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman	officer: CVP, CHIEF FINANCIAL OFFICER	C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p.	10 percent owner	795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini	officer: President & COO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig	director, officer: President and CEO	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536